骨外骨肉瘤:欧洲肌肉骨骼肿瘤学会266例患者研究
该多中心回顾性研究由欧洲肌肉骨骼肿瘤学会(EMSOS)16个中心提交1981至2014年诊治的骨外骨肉瘤(ESOS)患者资料,共266例符合条件。全部患者5年总生存(OS)为47%(95%CI 40-54%),术后完全缓解的211例局限期患者5年OS为51.4%(95%CI 44-59%)、5年无病生存(DFS)为43%(95%CI 35-51%)。多因素分析显示年龄≤40岁(P=0.05)、肿瘤大小(P=0.0001)和接受化疗(P=0.006)是生存的独立预后因素。
要点
- 266例ESOS患者5年OS为47%(95%CI 40-54%),其中50例(18.7%)初诊时已有转移。
- 211例局限期术后完全缓解患者5年OS为51.4%(95%CI 44-59%),5年DFS为43%(95%CI 35-51%)。
- 多因素分析中年龄≤40岁(P=0.05)、肿瘤大小(P=0.0001)和接受化疗(P=0.006)与生存显著相关。
核心结论
- 患者年龄和肿瘤大小是影响ESOS预后的因素。
- 接受围手术期化疗的患者生存率更高,且多药骨肉瘤型方案(包含多柔比星、异环磷酰胺和顺铂)显示出有利趋势。
研究设计与样本
- 欧洲肌肉骨骼肿瘤学会(EMSOS)成员提交骨外骨肉瘤(ESOS)患者机构数据的多中心回顾性研究。
- 共收集16个EMSOS中心1981年至2014年诊治的274例患者数据,其中266例符合条件纳入分析。
主要发现
- 50例(18.7%)在诊断时即有转移。
- 216例局限期患者中,211例(98%)接受手术(R0=70.6%,R1=27%)。
- 全部266例患者5年总生存(OS)为47%(95%CI 40-54%);转移性患者5年OS为27%(95%CI 13-41%)。
- 在术后达到完全缓解的211例局限期患者中,5年OS为51.4%(95%CI 44-59%),5年无病生存(DFS)为43%(95%CI 35-51%)。
- 121例(57.3%)接受辅助或新辅助化疗,80例(37.9%)接受放疗;骨肉瘤型化疗对比软组织肉瘤型(多柔比星±异环磷酰胺)方案显示出有利趋势。
关键数值与推荐
- 在术后完全缓解的211例患者中,单因素分析显示患者年龄、肿瘤大小、切缘和化疗是DFS和OS的有利预后因素。
- 多因素分析显示患者年龄(≤40岁对比>40岁)(P=0.05)、肿瘤大小(P=0.0001)和接受化疗(P=0.006)是生存的统计学显著预后因素。
临床怎么用
- 原文结论指出患者年龄和肿瘤大小是影响ESOS预后的因素。
- 原文结论指出接受围手术期化疗的患者生存率更高,且多药骨肉瘤型方案(包含多柔比星、异环磷酰胺和顺铂)显示出有利趋势。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prognosis of extraskeletal osteosarcoma (ESOS) is reported to be poorer than that of skeletal osteosarcoma. This multicenter retrospective study aimed to evaluate factors influencing ESOS prognosis. PATIENTS AND METHODS: Members of the European Musculoskeletal Oncology Society (EMSOS) submitted institutional data on patients with ESOS. RESULTS: Data from 274 patients treated from 1981 to 2014 were collected from 16 EMSOS centres; 266 patients were eligible. Fifty (18.7%) had metastases at diagnosis. Of 216 patients with localised disease, 211 (98%) underwent surgery (R0 = 70.6%, R1 = 27%). Five-year overall survival (OS) for all 266 patients was 47% (95% CI 40-54%). Five-year OS for metastatic patients was 27% (95% CI 13-41%). In the analysis restricted to the 211 localised patients who achieved complete remission after surgery 5-year OS was 51.4% (95% CI 44-59%) and 5-year disease-free survival (DFS) was 43% (95% CI 35-51%). One hundred twenty-one patients (57.3%) received adjuvant or neoadjuvant chemotherapy and 80 patients (37.9%) received radiotherapy. A favourable trend was seen for osteosarcoma-type chemotherapy versus soft tissue sarcoma-type (doxorubicin ± ifosfamide) regimens. For the 211 patients in complete remission after surgery, patient age, tumour size, margins and chemotherapy were positive prognostic factors for DFS and OS by univariate analysis. At multivariate analysis, patient age (≤40 years versus >40 years) (P = 0.05), tumour size (P = 0.0001) and receipt of chemotherapy (P = 0.006) were statistically significant prognostic factors for survival. CONCLUSION: Patient age and tumour size are factors influencing ESOS prognosis. Higher survival was observed in patients who received perioperative chemotherapy with a trend in favour of multiagent osteosarcoma-type regimen which included doxorubicin, ifosfamide and cisplatin.
引用
- Longhi A, Bielack SS, Grimer R, et al. Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients. Eur J Cancer. 2017. PMID: 28167373. doi:10.1016/j.ejca.2016.12.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。